MYLK3 and familial dilated cardiomyopathy: Non-symptomatic MYLK3 mutation-carriers in a pedigree with familial DCM could profit from early genetic diagnosis, and preemptive pharmacological treatment from an early disease stage, thereby contributing to a better prognosis for such DCM patients.